ANI Pharmaceuticals' (ANIP) shares were nearly 1% lower Monday after the drug maker said it has completed its acquisition of Alimera Sciences (ALIM).
ANI Pharmaceuticals said it continues to expect the transaction to drive high single-digit to low double-digit accretion in its adjusted non-GAAP earnings per share in 2025 with "substantially higher accretion thereafter."
The deal also should deliver an extra $35 million to $38 million in adjusted non-GAAP earnings before interest, taxes, depreciation and amortization in 2025, including around $10 million in expected cost synergies, the company said.
Price: 57.93, Change: -0.58, Percent Change: -0.99
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.